Login  /  Register  | 3 premium articles left before you must register.

Pfizer partners with nanotechnology firm

By Lee Howard

Publication: The Day

Published April 04. 2013 4:00AM
Massachusetts company BIND will collaborate on drug development

Pfizer Inc. said Wednesday that a new collaboration with Massachusetts-based BIND Therapeutics could eventually lead to drug work at company laboratories in Groton.

New York-based Pfizer confirmed a deal Wednesday that would pay BIND up to $200 million for each drug it works on that wins regulatory approval. The Cambridge company has a patented nanotechnology system that helps bypass the body's antibodies to deliver precise, therapeutic doses of new drugs to targeted areas.

"As any future investigational molecules from Pfizer advance into candidates, Groton could play an important role given the site's key development, safety and regulatory teams," Pfizer spokeswoman Lauren Starr said in an email.

Starr added that other Pfizer sites also might be involved in the collaboration with BIND. The company did not identify the types of diseases being targeted, but in the past BIND has worked on cancer, inflammatory and cardiovascular therapies.

"Pfizer has a strong legacy in targeted small molecule drug discovery and development and continues to be on the cutting edge of innovation in this area," said Rod MacKenzie, Groton's site leader and head of Pfizer's PharmaTherapeutics research division.

MacKenzie added that BIND's nanotechnology techniques bring the possibility of "optimizing the therapeutic potential" of orally administered drugs.

"BIND develops Accurins that outperform conventional drugs by selectively accumulating in diseased tissues and cells," the Cambridge company said in a release. "The result is higher drug concentrations at the site of action with minimal off-target exposure, leading to markedly better efficacy and safety."

BIND will get about $50 million in up-front payments from Pfizer for each Accurin it develops, with the potential of another $160 million or more for every drug that passes regulatory hurdles. Pfizer will decide on the drug targets, but it wouldn't say how many it will be aiming for, according to industry blog FiercePharma.

FiercePharma pointed out that the BIND collaboration "marks a key change for Pfizer," saying the company had over the past few years been spinning out drug programs rather than buying into them.

BIND is developing some of its own drugs in-house, but also has inked a key agreement with Amgen to produce new drug targets for teh California-based pharmaceutical company.

l.howard@theday.com

News by Town

Most Recent Poll
New data from the Centers for Disease Control and Prevention indicate that one in five boys and 11 percent of all schoolchildren are diagnosed with Attention Deficit Hyperactivity Disorder. Most take medication for it. What do you think of the epidemic?
I think the number of kids with ADHD has gone up because of better diagnoses.
10%
Kids wouldn't need medication if they had more structure at home and more time to blow off steam outdoors.
20%
Society should look at possible causes of the behaviors rather than just giving pills to kids.
31%
I bet a lot of these kids don't have ADHD. They are just badly behaved and have weak parents.
32%
Increased treatment is good; we should give kids all the help they need to thrive without judging them or their parents.
8%
Number of votes: 904

No current items found